Supplementary Figure S2 from PKCβ Inhibitor MS-553 Displays Preclinical Efficacy in Both Treatment-Naïve and BTK Inhibitor–Resistant Chronic Lymphocytic Leukemia
Year: 2026
Type: supplementary-materials
Abstract: PKCβ is accessible and upregulated in dual-refractory CLL.
Authors: Britten K. Gordon, Elizabeth M. Muhowski, Jyotsana Singh, Janani Ravikrishnan, Arnau Peris-Cuesta, Daisy Diaz Rohena, John R. Sanchez, Shanmugapriya Thangavadivel, Samon Benrashid, Alexander He, Alexander R. Marr, Andrew D. Mitchell, Jazmin M. Urrutia, Shrilekha Misra, Tzung-Huei Lai, Lianbo Yu, Brandi R. Walker, Elizabeth Perry, Sachet A. Shukla, Nicole R. Grieselhuber, Kerry A. Rogers, Rosa Lapalombella, James S. Blachly, Adam S. Kittai, Seema A. Bhat, Nitin Jain, William G. Wierda, John C. Byrd, Michael Niesman, Kai Zhang, Deepa Sampath, Jennifer A. Woyach
Language: English
Subfield: Genetics
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W7122535547